Navigation Links
SanBio Receives FDA Clearance to Initiate Cell Therapy Clinical Studies for Stroke Recovery
Date:6/16/2010

MOUNTAIN VIEW, Calif., June 16 /PRNewswire/ -- SanBio Inc. (www.san-bio.com) announced today that the United States Food and Drug Administration (FDA) has approved the clinical testing of their SB623 regenerative medicine product in patients suffering from disability caused by cerebral stroke. SB623 is derived from bone marrow stromal cells (MSCs) isolated from healthy adult donors.

This Phase 1/2a clinical trial will test the safety of SB623 when implanted in the damaged regions of the brains of stable stroke patients. "We are pleased and proud to be given the opportunity to move this therapeutic approach forward. This is the only clinical trial currently open in the United States testing the regenerative potential of cell therapy in the brain," said Kieta Mori, co-CEO of SanBio. "This cell product has the potential to change the lives of patients afflicted by stroke injury," said Dr. Douglas Kondziolka, the Peter J. Jannetta Professor of Neurological Surgery in the Department of Neurological Surgery, Director, Center for Brain Function and Behavior at the University of Pittsburgh School of Medicine and a Principal Investigator in the SB623 clinical trial. According to the American Heart Association, stroke is the third leading cause of death in the United States and the leading c
'/>"/>

SOURCE SanBio Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Baptist Health Lexington is the first facility in ... with Electrophysiology Services (EPS) Accreditation status from the Society of ... most common cardiac arrhythmia and has become recognized as a ... and possible death. More than 5 million patients in ... the numbers are rapidly increasing as the population ages. ...
(Date:12/19/2014)... CITY, Kan. , Dec. 18, 2014 /PRNewswire/ ... PETX ), a biopharmaceutical company focused on the ... companion animals, today announced positive results from its ... innovative drug for treating pain in dogs with ... improvements in pain assessment scores that were statistically ...
(Date:12/19/2014)... separating membrane market has witnessed robust development with the ... as a later starter. In 2012, the size of ... billion, with the proportion worldwide soaring to 16.3%. It is ... will continue its growth rate by around 20% in the ... to roughly RMB25 billion. An integrated membrane industrial ...
Breaking Medicine Technology:Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3
... 30 Sirion Therapeutics, Inc. announced today ... products, pipeline and research will be presented ... Association for Research in Vision and Ophthalmology ... http://www.newscom.com/cgi-bin/prnh/20080220/CLW064LOGO )These presentations include ...
... Two Phase 3 studies to start in the second ... Bayer HealthCare AG and Regeneron Pharmaceuticals, Inc. (Nasdaq: ... are extending their global development program for VEGF Trap-Eye, ... diseases, to include Central Retinal Vein Occlusion (CRVO). The ...
Cached Medicine Technology:Sirion Therapeutics Announces Clinical Data Presentations at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2Sirion Therapeutics Announces Clinical Data Presentations at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 3Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion 2Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion 3Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion 4Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion 5
(Date:12/22/2014)... 2014 Coral Gables is preparing to welcome ... Troopers, with its new clinic location set to open in ... hassle out of dealing with this common childhood parasite by ... two salon clinic locations in South Florida, or in the ... decision to expand developed naturally out of the demand for ...
(Date:12/22/2014)... New York (PRWEB) December 22, 2014 The ... a staple of the season. Many may be thinking about ... a span of a few weeks. Health Republic Insurance of ... of Registered Dietitian, Andrea Chernus, to provide some smart ideas ... and stay healthy. , 1)    Avoid arriving at a holiday gathering ...
(Date:12/22/2014)... Shanghai, China (PRWEB) December 22, 2014 ... for MabThera (rituximab) for the treatment of non-Hodgkin’s lymphoma ... Health , a leading global healthcare consulting firm. MabThera ... B-cell lymphoma (DLBCL), the most common form of NHL. ... Market Access and Barriers,” the incidence of NHL in ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Only weeks ... southern and mid-western cities to have a battery manufacturer ... TalkLocal ( http://www.talklocal.com ) is launching in Henderson ... economy. , “A strong manufacturing sector is going ... founder Gurpreet Singh explained, “and TalkLocal works with small ...
(Date:12/22/2014)... 2014 Pasadena sleep apnea ... sleep apnea. Drowsy drivers are 15 times more likely ... well-rested, and some experts believe that sleep-deprived drivers may ... drivers. Unfortunately, millions of Americans may be sleep-deprived without ... Sleep Medicine, about 18 million Americans have sleep apnea, ...
Breaking Medicine News(10 mins):Health News:Professional In-Home All-Natural Lice Removal Service Expands to Coral Gables and surrounding areas. 2Health News:Health Republic Insurance of New York Offers Five Simple Tips to Eat Healthy During the Holidays 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:TalkLocal Launches in Henderson Weeks Following New Megafactory, New Jobs Announcement 2Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2
... latest issue of Deutsches rzteblatt International ( ... research group presents epidemiological data. The authors surveyed ... specializing in the treatment of HIV patients in the ... to analyze the largest collection of data on the ...
... care information systems is a multibillion dollar industry. The ... to talk to each other regularly attract media comment. However ... Open Source, that could address many of these problems, because ... systems. Now new research by the University of Warwick,s ...
... Metabolomics is a post-genomic research field for analysis of ... approaches offer an analysis of metabolite level changes in ... in identifying the new diagnostic markers and therapeutic targets ... scarce. A research article to be published on ...
... an inflammatory obliterative cholangiopathy with unknown etiology, leading ... as an indispensable research tool for gene expression ... underlying BA, and allows the simultaneous analysis of ... studies have been performed to investigate the gene ...
... The best prescription for patients with venous leg ulcers is ... A five-year study led from the University of Leeds ... the healing process of leg ulceration contrary to what ... cheaper and easier to deliver, work just as well, the ...
... Reporter , MONDAY, March 7 (HealthDay News) -- Interactive ... kids, metabolisms to levels typically seen with moderate or ... the effect of six forms of so-called "exergaming" on ... (BMIs) at a youth fitness research and training center ...
Cached Medicine News:Health News:Resaerch finds open-source software is actually more secure for health care IT 2Health News:Laughter really is the best medicine (for leg ulcers) 2Health News:Video Games That Make Kids Move Burn Calories 2
Inquire...
Inquire...
... X-22 Series is up to 10 inches/ 25 cm ... 11 rotors, the Allegra X-22 Series is the space-saving ... Only 18 inches / 46 cm wide • 11 ... 3 different ways to Spin 1.5 mL & ...
... Optimal for Subcellular Fractionation, Proteins ... g (30,000 rpm) with fixed-angle ... 0.25 up to 85 mL ... C to 40° C • ...
Medicine Products: